Autolus Therapeutics shares are trading higher after Needham maintained a Buy rating on the stock and raised its price target from $8 to $9.
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics' stock price increased following Needham's decision to maintain a Buy rating and raise its price target from $8 to $9.
February 12, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Autolus Therapeutics' shares are trading higher after an analyst upgrade, with Needham maintaining a Buy rating and increasing the price target from $8 to $9.
The increase in Autolus Therapeutics' stock price is directly attributed to Needham's positive analyst rating and raised price target. Such analyst actions often lead to short-term price increases as they signal confidence in the company's future performance to the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100